{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T02:17:19Z","timestamp":1785377839312,"version":"3.55.0"},"reference-count":126,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.rdc.2025.05.005","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T15:25:22Z","timestamp":1749482722000},"page":"447-468","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Novel Therapeutic Targets in the Management of Psoriatic Disease"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3406-8890","authenticated-orcid":false,"given":"Beth A.","family":"Childs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6514-4353","authenticated-orcid":false,"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rdc.2025.05.005_bib1","article-title":"Psoriasis prevalence among adults in the United States","author":"Smith","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.rdc.2025.05.005_bib2","article-title":"Psoriatic arthritis: a comprehensive review for the dermatologist(.) Part II: screening and management","author":"Elman","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.rdc.2025.05.005_bib3","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/art.41765","article-title":"Moving the goalpost toward remission: the case for combination immunomodulatory therapies in psoriatic arthritis","volume":"73","author":"Scher","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.rdc.2025.05.005_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22052719","article-title":"The role of tumor necrosis factor alpha (TNF-alpha) in autoimmune disease and current TNF-alpha inhibitors in therapeutics","volume":"22","author":"Jang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.rdc.2025.05.005_bib5","article-title":"Psoriatic arthritis: a comprehensive review for the dermatologist part I: epidemiology, comorbidities, pathogenesis, and diagnosis","author":"Perez-Chada","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.rdc.2025.05.005_bib6","article-title":"Update on non-infectious uveitis treatment: anti-TNF-alpha and beyond","volume":"4","author":"Chauhan","year":"2024","journal-title":"Front Ophthalmol (Lausanne)"},{"issue":"6","key":"10.1016\/j.rdc.2025.05.005_bib7","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2025.05.005_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1479557","article-title":"Corrigendum: an orally available small molecule that targets soluble TNF to deliver anti-TNF biologic-like efficacy in rheumatoid arthritis","volume":"15","author":"Vugler","year":"2024","journal-title":"Front Pharmacol"},{"issue":"5","key":"10.1016\/j.rdc.2025.05.005_bib9","doi-asserted-by":"crossref","first-page":"217","DOI":"10.4330\/wjc.v15.i5.217","article-title":"Acute heart failure as an adverse event of tumor necrosis factor inhibitor therapy in inflammatory bowel disease: a review of the literature","volume":"15","author":"Grillo","year":"2023","journal-title":"World J Cardiol"},{"key":"10.1016\/j.rdc.2025.05.005_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102942","article-title":"Use of anti-TNF-alpha therapy in Crohn\u2019s disease is associated with increased incidence of multiple sclerosis","volume":"51","author":"Avasarala","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10.1016\/j.rdc.2025.05.005_bib11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/annrheumdis-2017-212196","article-title":"Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study","volume":"77","author":"Mariette","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2025.05.005_bib12","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.3389\/fimmu.2019.03096","article-title":"IL-17A in psoriasis and beyond: cardiovascular and metabolic implications","volume":"10","author":"von Stebut","year":"2019","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.rdc.2025.05.005_bib13","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/bjd.19509","article-title":"A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial","volume":"184","author":"Blauvelt","year":"2021","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.005_bib14","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2024.2349658","article-title":"Comparative analysis of persistence and remission with guselkumab versus secukinumab and ixekizumab in the United States","volume":"35","author":"Zhdanava","year":"2024","journal-title":"J Dermatol Treat"},{"issue":"4","key":"10.1016\/j.rdc.2025.05.005_bib15","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s40744-020-00250-3","article-title":"Efficacy and safety of ixekizumab with or without methotrexate in biologic-naive patients with psoriatic arthritis: 52-week results from SPIRIT-H2H Study","volume":"7","author":"Smolen","year":"2020","journal-title":"Rheumatol Ther"},{"issue":"10235","key":"10.1016\/j.rdc.2025.05.005_bib16","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet"},{"issue":"10273","key":"10.1016\/j.rdc.2025.05.005_bib17","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.rdc.2025.05.005_bib18","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1093\/bjd\/ljac089","article-title":"Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III\/IIIb trials","volume":"188","author":"Kokolakis","year":"2023","journal-title":"Br J Dermatol"},{"issue":"12","key":"10.1016\/j.rdc.2025.05.005_bib19","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1007\/s13555-024-01295-w","article-title":"Bimekizumab efficacy in high-impact areas: pooled 2-year analysis in scalp, nail, and palmoplantar psoriasis from phase 3\/3b randomized controlled trials","volume":"14","author":"Merola","year":"2024","journal-title":"Dermatol Ther"},{"issue":"10370","key":"10.1016\/j.rdc.2025.05.005_bib20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0140-6736(22)02302-9","article-title":"Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)","volume":"401","author":"McInnes","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.005_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003855","article-title":"Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL","volume":"10","author":"Coates","year":"2024","journal-title":"RMD Open"},{"issue":"2","key":"10.1016\/j.rdc.2025.05.005_bib22","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1136\/ard-2023-224803","article-title":"Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies","volume":"83","author":"Baraliakos","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.005_bib23","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1136\/annrheumdis-2024-eular.1295","article-title":"OP0195 Efficacy and safety of sonelokimab, a novel IL-17A- AND IL-17F-inhibiting NANOBODY\u00ae, in patients with active psoriatic arthritis (PsA): results from the global, randomized, double-blind, placebo-controlled phase 2 argo trial","volume":"83","author":"McInnes","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.rdc.2025.05.005_bib24","article-title":"Efficacy and safety of sonelokimab, a Novel IL-17A- and IL-17F-inhibiting nanobody, in patients with active PsA: 24-week results from a global, randomized, double-blind, placebo-controlled phase 2 trial","volume":"76","author":"McInnes","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.005_bib25","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1093\/bjd\/ljad315","article-title":"Safety, tolerability, pharmacokinetics and efficacy of HB0017, a humanized monoclonal antibody that targets interleukin-17A, in healthy participants and patients with moderate-to-severe plaque psoriasis","volume":"190","author":"Jiang","year":"2023","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.rdc.2025.05.005_bib26","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/cpt.3185","article-title":"Safety, tolerability, and pharmacokinetics of an oral small molecule inhibitor of IL-17A (LY3509754): a phase i randomized placebo-controlled study","volume":"115","author":"Datta-Mannan","year":"2024","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.005_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16010111","article-title":"Emerging oral therapies for the treatment of psoriasis: a review of pipeline agents","volume":"16","author":"Drakos","year":"2024","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.rdc.2025.05.005_bib28","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40257-024-00845-4","article-title":"Treatment of psoriasis patients with latent tuberculosis using IL-17 and IL-23 inhibitors: a retrospective, multinational, multicentre study","volume":"25","author":"Torres","year":"2024","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"10.1016\/j.rdc.2025.05.005_bib29","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.jaad.2024.07.1473","article-title":"Interleukin 23 versus interleukin 12\/23 inhibitors on preventing incidental psoriatic arthritis in patients with psoriasis? A real-world comparison from the TriNetX Global Collaborative Network","volume":"91","author":"Tsai","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"10230","key":"10.1016\/j.rdc.2025.05.005_bib30","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFalpha inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"issue":"10230","key":"10.1016\/j.rdc.2025.05.005_bib31","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.005_bib32","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13063-022-06945-y","article-title":"The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-blind, placebo-controlled trial","volume":"24","author":"Ritchlin","year":"2023","journal-title":"Trials"},{"issue":"9","key":"10.1016\/j.rdc.2025.05.005_bib33","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamadermatol.2024.2463","article-title":"Noninferiority of 16-week vs 8-week guselkumab dosing in super responders for maintaining control of psoriasis: the GUIDE randomized clinical trial","volume":"160","author":"Eyerich","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.rdc.2025.05.005_bib34","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jaad.2023.07.1024","article-title":"Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up","volume":"89","author":"Papp","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.rdc.2025.05.005_bib35","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1093\/rheumatology\/keac605","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study","volume":"62","author":"Ostor","year":"2023","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.rdc.2025.05.005_bib36","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s40744-024-00657-2","article-title":"Efficacy and safety of risankizumab for active psoriatic arthritis: 100-week results from the KEEPsAKE 2 Randomized Clinical Trial","volume":"11","author":"Ostor","year":"2024","journal-title":"Rheumatol Ther"},{"issue":"3","key":"10.1016\/j.rdc.2025.05.005_bib37","article-title":"FC23 High induction dosing of risankizumab in patients with moderate-to-severe plaque leads to marked suppression of resident memory T cell number and function in resolved psoriatic skin","volume":"191","author":"Blauvelt","year":"2024","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.rdc.2025.05.005_bib38","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.rdc.2025.05.005_bib39","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1136\/annrheumdis-2020-219014","article-title":"Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2025.05.005_bib40","unstructured":"Zaraa I, Clin4All. Efficacy of tildrakizumab in difficult-to-treat areas in psoriasis (ZODIPSO). ClinicalTrials.gov ID: NCT05938361. Accessed 1\/30\/2025, 2025."},{"issue":"3","key":"10.1016\/j.rdc.2025.05.005_bib41","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/14712598.2024.2325547","article-title":"Tildrakizumab: the value of a personalized and flexible approach for treating moderate-to-severe plaque psoriasis in patients with high body weight or high disease burden","volume":"24","author":"Dapavo","year":"2024","journal-title":"Expet Opin Biol Ther"},{"issue":"3","key":"10.1016\/j.rdc.2025.05.005_bib42","article-title":"P130 ORKA-001: a novel extended half-life monoclonal Antibody targeting IL-23 with the potential to improve upon currently available therapies for psoriasis","volume":"191","author":"Kwan","year":"2024","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.rdc.2025.05.005_bib43","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1056\/NEJMoa2308713","article-title":"An oral interleukin-23-receptor antagonist peptide for plaque psoriasis","volume":"390","author":"Bissonnette","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rdc.2025.05.005_bib44","article-title":"FRONTIER-2: a phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis","author":"Ferris","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.rdc.2025.05.005_bib46","author":"Janssen Research & Development"},{"key":"10.1016\/j.rdc.2025.05.005_bib47","unstructured":"Janssen Research & Development L. A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2). Available at: https:\/\/clinicaltrials.gov\/study\/NCT06220604 (Accessed 2 June 2025)."},{"issue":"10463","key":"10.1016\/j.rdc.2025.05.005_bib49","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/S0140-6736(24)01750-1","article-title":"IL-23 inhibition for chronic inflammatory disease","volume":"404","author":"Jairath","year":"2024","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.rdc.2025.05.005_bib50","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.rdc.2025.05.005_bib51","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.rdc.2025.05.005_bib52","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/24755303211047479","article-title":"TNF-alpha inhibitors and ustekinumab for the treatment of psoriasis: therapeutic utility in the era of IL-17 and IL-23 inhibitors","volume":"7","author":"Hong","year":"2022","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"6","key":"10.1016\/j.rdc.2025.05.005_bib53","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1136\/annrheumdis-2013-204741","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2025.05.005_bib54","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.670398","article-title":"Adverse events associated with anti-IL-23 agents: clinical evidence and possible mechanisms","volume":"12","author":"Ru","year":"2021","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.005_bib55","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jid.2018.07.025","article-title":"A critical role of the IL-1beta-IL-1R signaling pathway in skin inflammation and psoriasis pathogenesis","volume":"139","author":"Cai","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.005_bib56","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41392-023-01655-6","article-title":"Signaling pathways and targeted therapies for psoriasis","volume":"8","author":"Guo","year":"2023","journal-title":"Signal Transduct Targeted Ther"},{"issue":"3","key":"10.1016\/j.rdc.2025.05.005_bib57","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s002960050111","article-title":"Serum levels of IL-10, IL-6, IL-1ra, and sIL-2R in patients with psoriatic arthritis","volume":"19","author":"Elkayam","year":"2000","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.rdc.2025.05.005_bib58","doi-asserted-by":"crossref","DOI":"10.1177\/20587384211006584","article-title":"Off-label use of anti-IL-1 drugs in rheumatic diseases","volume":"35","author":"Stefania","year":"2021","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"6","key":"10.1016\/j.rdc.2025.05.005_bib59","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.jaad.2022.07.065","article-title":"Anakinra for refractory pustular psoriasis: a phase II, open-label, dose-escalation trial","volume":"87","author":"Naik","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.rdc.2025.05.005_bib60","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/10600280241252688","article-title":"Spesolimab: a review of the first IL-36 blocker approved for generalized pustular psoriasis","volume":"59","author":"Pathak","year":"2025","journal-title":"Ann Pharmacother"},{"issue":"26","key":"10.1016\/j.rdc.2025.05.005_bib61","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa2111563","article-title":"Trial of spesolimab for generalized pustular psoriasis","volume":"385","author":"Bachelez","year":"2021","journal-title":"N Engl J Med"},{"issue":"10412","key":"10.1016\/j.rdc.2025.05.005_bib62","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(23)01378-8","article-title":"Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial","volume":"402","author":"Morita","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.rdc.2025.05.005_bib63","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1093\/bjd\/ljad128","article-title":"Imsidolimab: an emerging biological therapy for generalized pustular psoriasis","volume":"189","author":"Gleeson","year":"2023","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.rdc.2025.05.005_bib64","first-page":"249","article-title":"Role of Interleukin-36 in inflammatory joint diseases","volume":"52","author":"Wang","year":"2023","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"key":"10.1016\/j.rdc.2025.05.005_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.imlet.2024.106926","article-title":"Autoantibody mediated deficiency of IL-36-receptor antagonist in a subset of patients with psoriasis and psoriatic arthritis","volume":"270","author":"Hoffmann","year":"2024","journal-title":"Immunol Lett"},{"issue":"7","key":"10.1016\/j.rdc.2025.05.005_bib66","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1080\/09546634.2022.2089335","article-title":"Generalized pustular psoriasis: the new era of treatment with IL-36 receptor inhibitors","volume":"33","author":"Macaes","year":"2022","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.rdc.2025.05.005_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115848","article-title":"Synthesis and clinical application of small-molecule inhibitors of Janus kinase","volume":"261","author":"Zhang","year":"2023","journal-title":"Eur J Med Chem"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.005_bib68","first-page":"275","article-title":"Efficacy and safety of upadacitinib in patients with psoriatic arthritis: 2-year results from the phase 3 SELECT-PsA 1 Study","volume":"10","author":"McInnes","year":"2023","journal-title":"Rheumatol Ther"},{"issue":"10349","key":"10.1016\/j.rdc.2025.05.005_bib69","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(22)01212-0","article-title":"Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Deodhar","year":"2022","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.rdc.2025.05.005_bib70","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","article-title":"Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.005_bib71","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1136\/annrheumdis-2024-eular.1426","article-title":"POS0978 direct and indirect effects of upadacitinib or adalimumab on pain in psoriatic arthritis: results from a randomized phase 3 study","volume":"83","author":"Taylor","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2025.05.005_bib72","first-page":"97","article-title":"Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives","volume":"9","author":"Ly","year":"2019","journal-title":"Psoriasis (Auckl)"},{"issue":"8","key":"10.1016\/j.rdc.2025.05.005_bib73","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1097\/CM9.0000000000000711","article-title":"A novel treatment for psoriatic arthritis: Janus kinase inhibitors","volume":"133","author":"Chen","year":"2020","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.005_bib74","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s41927-022-00287-7","article-title":"Efficacy and safety of JAK inhibitors in the treatment of psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"6","author":"Sarabia","year":"2022","journal-title":"BMC Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.005_bib75","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/bjd\/ljad098","article-title":"Efficacy and safety of topical brepocitinib cream for mild-to-moderate chronic plaque psoriasis: a phase IIb randomized double-blind vehicle-controlled parallel-group study","volume":"189","author":"Landis","year":"2023","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.rdc.2025.05.005_bib76","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/art.42519","article-title":"Efficacy and Safety of the TYK2\/JAK1 inhibitor brepocitinib for active psoriatic arthritis: a phase IIb randomized controlled trial","volume":"75","author":"Mease","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.005_bib77","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2024.2397477","article-title":"Janus kinase inhibitors and adverse events of acne in dermatologic indications: a systematic review and network meta-analysis","volume":"35","author":"Chen","year":"2024","journal-title":"J Dermatol Treat"},{"key":"10.1016\/j.rdc.2025.05.005_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1264667","article-title":"The efficacy and safety of tyrosine kinase 2 inhibitor deucravacitinib in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Qiu","year":"2023","journal-title":"Front Med"},{"issue":"5","key":"10.1016\/j.rdc.2025.05.005_bib79","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/DCR.0000000000003137","article-title":"Tofacitinib is associated with increased risk of postoperative venous thromboembolism in patients with ulcerative colitis","volume":"67","author":"Russell","year":"2024","journal-title":"Dis Colon Rectum"},{"issue":"2","key":"10.1016\/j.rdc.2025.05.005_bib80","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.36849\/JDD.7645","article-title":"A case series of TNF inhibitor-induced psoriasis successfully treated with upadacitinib","volume":"23","author":"Woodbury","year":"2024","journal-title":"J Drugs Dermatol"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.005_bib81","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.rdc.2025.05.005_bib82","doi-asserted-by":"crossref","first-page":"590","DOI":"10.25259\/IJDVL_775_2023","article-title":"Comparative efficacy and safety of JAK\/TYK2 inhibitors and other oral drugs for moderate-to-severe plaque psoriasis: systematic review and network meta-analysis","volume":"90","author":"Zheng","year":"2024","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"10","key":"10.1016\/j.rdc.2025.05.005_bib83","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/jamadermatol.2024.2701","article-title":"Tyrosine kinase 2 inhibition with zasocitinib (TAK-279) in psoriasis: a randomized clinical trial","volume":"160","author":"Armstrong","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"12","key":"10.1016\/j.rdc.2025.05.005_bib84","doi-asserted-by":"crossref","DOI":"10.1111\/cts.70094","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral allosteric TYK2 inhibitor ESK-001 using a randomized, double-blind, placebo-controlled study design","volume":"17","author":"Ucpinar","year":"2024","journal-title":"Clin Transl Sci"},{"issue":"4","key":"10.1016\/j.rdc.2025.05.005_bib85","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1177\/24755303231201336","article-title":"Deucravacitinib: a novel TYK2 inhibitor for the treatment of moderate-to-severe psoriasis","volume":"8","author":"Kingston","year":"2023","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.005_bib86","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics16010023","article-title":"Phosphodiesterase-4 inhibition in the management of psoriasis","volume":"16","author":"Crowley","year":"2023","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.005_bib87","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)","volume":"73","author":"Papp","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.rdc.2025.05.005_bib88","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/bjd.14164","article-title":"Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)","volume":"173","author":"Paul","year":"2015","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.005_bib89","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jaad.2021.07.040","article-title":"Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial","volume":"86","author":"Stein Gold","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"10.1016\/j.rdc.2025.05.005_bib90","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1136\/ard-2024-225833","article-title":"Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.rdc.2025.05.005_bib91","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/annrheumdis-2015-207963","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)","volume":"75","author":"Edwards","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2025.05.005_bib92","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s40257-022-00703-1","article-title":"Combination therapy with apremilast and biologics for psoriasis: a systematic review","volume":"23","author":"Gyldenlove","year":"2022","journal-title":"Am J Clin Dermatol"},{"issue":"10284","key":"10.1016\/j.rdc.2025.05.005_bib93","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/S0140-6736(21)00440-2","article-title":"IL17A\/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study","volume":"397","author":"Papp","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.rdc.2025.05.005_bib94","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065994","article-title":"NANOBODIES(R): a review of diagnostic and therapeutic applications","volume":"24","author":"Jin","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1\u20132","key":"10.1016\/j.rdc.2025.05.005_bib95","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11103-020-01082-z","article-title":"Applications of nanobodies in plant science and biotechnology","volume":"105","author":"Wang","year":"2021","journal-title":"Plant Mol Biol"},{"issue":"4","key":"10.1016\/j.rdc.2025.05.005_bib96","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S2468-1253(22)00427-7","article-title":"Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial","volume":"8","author":"Feagan","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.rdc.2025.05.005_bib97","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jdcr.2024.02.036","article-title":"The use of dual biologic therapy for the management of recalcitrant psoriasis","volume":"47","author":"Finnegan","year":"2024","journal-title":"JAAD Case Rep"},{"issue":"10","key":"10.1016\/j.rdc.2025.05.005_bib98","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.jdcr.2019.08.015","article-title":"Dual biologic therapy for recalcitrant psoriasis and psoriatic arthritis","volume":"5","author":"Thibodeaux","year":"2019","journal-title":"JAAD Case Rep"},{"issue":"2","key":"10.1016\/j.rdc.2025.05.005_bib99","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/bjd\/ljae131","article-title":"Efficacy and safety of nemolizumab and topical corticosteroids for prurigo nodularis: results from a randomized double-blind placebo-controlled phase II\/III clinical study in patients aged >\/= 13 years","volume":"191","author":"Yokozeki","year":"2024","journal-title":"Br J Dermatol"},{"issue":"11","key":"10.1016\/j.rdc.2025.05.005_bib100","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/j.1468-3083.2012.04609.x","article-title":"Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study","volume":"27","author":"Ahern","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.005_bib101","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/RHU.0000000000001949","article-title":"Glucagon-like peptide 1 receptor agonists in patients with inflammatory arthritis or psoriasis: a scoping review","volume":"30","author":"Karacabeyli","year":"2024","journal-title":"J Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.005_bib102","doi-asserted-by":"crossref","first-page":"65","DOI":"10.47360\/1995-4484-2024-65-80","article-title":"Effectiveness and safety of BCD180, anti-TRBV9+ T-lymphocytes monoclonal antibody in patients with active radiographic axial spondyloarthritis: 36-week results of double-blind randomized placebo-controlled phase II clinical study ELEFTA","volume":"62","author":"Nasonov","year":"2024","journal-title":"Rheumatology Science and Practice"},{"key":"10.1016\/j.rdc.2025.05.005_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.108409","article-title":"CAR Treg: a new approach in the treatment of autoimmune diseases","volume":"102","author":"Beheshti","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.rdc.2025.05.005_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2025.103369","article-title":"CAR-T cell targeting three receptors on autoreactive B cells for systemic lupus erythematosus therapy","volume":"151","author":"Uppin","year":"2025","journal-title":"J Autoimmun"},{"issue":"2","key":"10.1016\/j.rdc.2025.05.005_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101267","article-title":"Preclinical specificity & activity of a fully human 41BB-expressing anti-CD19 CART- therapy for treatment-resistant autoimmune disease","volume":"32","author":"Peng","year":"2024","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.rdc.2025.05.005_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152479","article-title":"Advancing autoimmune Rheumatic disease treatment: CAR-T cell therapies - evidence, safety, and future directions","volume":"67","author":"Ohno","year":"2024","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.005_bib107","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s12974-024-03262-w","article-title":"MOG-specific CAR Tregs: a novel approach to treat multiple sclerosis","volume":"21","author":"Frikeche","year":"2024","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.rdc.2025.05.005_bib108","article-title":"Incidentally cured psoriasis in a patient with refractory\/relapsed diffuse large B-cell lymphoma receiving CD19 CAR-T cell therapy: a case report","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.rdc.2025.05.005_bib109","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1111\/bjd.20517","article-title":"The promise and challenges of cell therapy for psoriasis","volume":"185","author":"Lwin","year":"2021","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.rdc.2025.05.005_bib110","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/17425255.2024.2337749","article-title":"Clinical pharmacokinetics and pharmacodynamics of topical non-biological therapies for psoriasis patients","volume":"20","author":"Lo","year":"2024","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"5","key":"10.1016\/j.rdc.2025.05.005_bib111","first-page":"357","article-title":"ZORYVE(TM) (Roflumilast) cream: a topical phosphodiesterase-4 inhibitor for the treatment of psoriasis","volume":"21","author":"Gupta","year":"2023","journal-title":"Skinmed"},{"issue":"6","key":"10.1016\/j.rdc.2025.05.005_bib112","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1111\/jdv.18925","article-title":"Tapinarof for psoriasis and atopic dermatitis: 15 years of clinical research","volume":"37","author":"Bissonnette","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"10.1016\/j.rdc.2025.05.005_bib113","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa2314076","article-title":"Phase 2 Trial of Anti-TL1A monoclonal antibody tulisokibart for ulcerative colitis","volume":"391","author":"Sands","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.rdc.2025.05.005_bib114","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1016\/S2665-9913(23)00120-0","article-title":"Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study","volume":"5","author":"Papp","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.005_bib115","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1186\/s12876-023-03078-7","article-title":"Long-term safety of brazikumab in the open-label period of a randomized phase 2a study of patients with Crohn\u2019s disease","volume":"23","author":"Danese","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.rdc.2025.05.005_bib116","author":"Cooper"},{"issue":"12","key":"10.1016\/j.rdc.2025.05.005_bib117","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1080\/14712598.2022.2113872","article-title":"New frontiers in personalized medicine in psoriasis","volume":"22","author":"Camela","year":"2022","journal-title":"Expet Opin Biol Ther"},{"key":"10.1016\/j.rdc.2025.05.005_bib118","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1136\/annrheumdis-2023-eular.5466","article-title":"AB0111 Characterizing the pre-disease state of psoriatic arthritis: CXCL10 levels are associated with subclinical synovitis in patients with psoriasis","volume":"82","author":"Pulito-Cueto","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.rdc.2025.05.005_bib119","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004176","article-title":"Clinical, genetic and omics-based biomarkers that might support the identification of the development of psoriatic arthritis in individuals with psoriasis: a narrative review of the literature","volume":"10","author":"Grohmann","year":"2024","journal-title":"RMD Open"},{"issue":"9","key":"10.1016\/j.rdc.2025.05.005_bib120","article-title":"Deucravacitinib, an oral,selective,allosteric tyrosine kinase 2 inhibitor, in patients withmoderate to severe scalp psoriasis: efficacy and safety results of a phase 3b\/4, multicenter, randomized, double-blinded, placebo-controlled trial (PSORIATYK SCALP)","volume":"76","author":"Griffiths","year":"2024","journal-title":"Am Coll Rheumatol"},{"issue":"3","key":"10.1016\/j.rdc.2025.05.005_bib121","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jaad.2023.10.020","article-title":"Efficacy and safety of apremilast in patients with moderate-to-severe genital psoriasis: results from DISCREET, a phase 3 randomized, double-blind, placebo-controlled trial","volume":"90","author":"Merola","year":"2024","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.rdc.2025.05.005_bib122","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41419-022-04523-3","article-title":"Advances in the pathogenesis of psoriasis: from keratinocyte perspective","volume":"13","author":"Zhou","year":"2022","journal-title":"Cell Death Dis"},{"issue":"2","key":"10.1016\/j.rdc.2025.05.005_bib123","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s13555-022-00878-9","article-title":"Novel therapies in plaque psoriasis: a review of tyrosine kinase 2 inhibitors","volume":"13","author":"Martin","year":"2023","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.rdc.2025.05.005_bib124","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115371","article-title":"Functions of the aryl hydrocarbon receptor (AHR) beyond the canonical AHR\/ARNT signaling pathway","volume":"208","author":"Sondermann","year":"2023","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"10.1016\/j.rdc.2025.05.005_bib125","first-page":"1","article-title":"Small molecules: an overview of emerging therapeutic options in the treatment of psoriasis","volume":"18","author":"Gooderham","year":"2013","journal-title":"Skin Therapy Lett"},{"key":"10.1016\/j.rdc.2025.05.005_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105180","article-title":"The aryl hydrocarbon receptor: an environmental effector in the pathogenesis of fibrosis","volume":"160","author":"Shi","year":"2020","journal-title":"Pharmacol Res"},{"issue":"2","key":"10.1016\/j.rdc.2025.05.005_bib127","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/ncprheum0987","article-title":"New insights into the pathogenesis and genetics of psoriatic arthritis","volume":"5","author":"Nograles","year":"2009","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2025.05.005_bib128","first-page":"16","article-title":"From the masterclasses in dermatology 2024 meeting: updates in psoriasis treatments","volume":"18","author":"Childs","year":"2025","journal-title":"J Clin Aesthet Dermatol"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X25000286?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X25000286?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T00:16:04Z","timestamp":1752711364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X25000286"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":126,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0889857X25000286"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2025.05.005","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Therapeutic Targets in the Management of Psoriatic Disease","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2025.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}